Loading…
H.R. 1082119th CongressPassed one chamberLatest action Jun 24, 2025Decoded by AI · checked against the record
Official title: Shandra Eisenga Human Cell and Tissue Product Safety Act
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
HR 1082 adds fines and FDA transparency rules for human tissue products like donated skin, bone, and tendons.
40-second read · 5 questions answered below
The bill requires HHS to run a public education campaign on the risks, benefits, and screening of human cell and tissue products. It also creates financial penalties for safety rule violations and directs the FDA to publish more information about inspections and facility oversight, plus report to Congress by September 2026.
Patients receiving tissue-based treatments, healthcare providers, tissue banks and processing companies, and FDA regulatory staff are affected.
The changes aim to hold tissue processors accountable for safety lapses and give patients, providers, and Congress clearer information about how the industry is regulated.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it passed the House, and the official record shows nothing new since. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.